Exicure マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Paul Kang

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	1.3yrs
CEOの所有権	n/a
経営陣の平均在職期間	1.3yrs
取締役会の平均在任期間	1.3yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Paul Kang (62 yo)

1.3yrs

在職期間

Mr. Paul Kang is Director of Exicure, Inc. from February 24, 2023 and serves as its Chief Executive Officer since August 21, 2023 and has been its President. He is associated with CBI USA Inc. Mr. Kang beg...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Paul Kang	CEO, President & Director	1.3yrs	データなし	データなし
Jiyoung Hwang	CFO, Secretary & Director	1.3yrs	データなし	データなし
Joshua Miller	Chief Accounting Officer	1.5yrs	データなし	0.011% € 3.7k

1.3yrs

平均在職期間

48yo

平均年齢

経験豊富な経営陣: 2H0の経営陣は経験豊富とはみなされません ( 1.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Paul Kang	CEO, President & Director	1.8yrs	データなし	データなし
Jiyoung Hwang	CFO, Secretary & Director	1.8yrs	データなし	データなし
Michael Hodges	Member of Advisory Board	no data	データなし	データなし
Amy Paller	Member of Advisory Board	no data	データなし	データなし
Henry Paulson	Member of Advisory Board	4.9yrs	データなし	データなし
Hojoon Lee	Director	1.3yrs	データなし	データなし
Hyuk Ko	Independent Director	1.3yrs	データなし	データなし
Dongho Lee	Independent Director	1.3yrs	データなし	データなし
Minhee Eom	Independent Director	1.2yrs	データなし	データなし

1.3yrs

平均在職期間

56.5yo

平均年齢

経験豊富なボード: 2H0の取締役会は経験豊富ではない ( 1.3年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Exicure マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

High number of new and inexperienced directors

Exicure, Inc. Appoints Anna Chukaeva as Senior Vice President, Head of Corporate Development and Bioinformatics

Exicure, Inc., Annual General Meeting, Jun 28, 2024

No independent directors

Exicure, Inc. Appoints Minhee Eom to the Board

Exicure, Inc. Announces Executive Changes

Recent updates

Exicure Request for Subsequent Extension to Nasdaq Hearings Panel Till December 17

Nasdaq Hearings Panel Grants Exicure Extension for Continued Listing on The Nasdaq Capital Market, Compliance Required by November 14, 2024

Exicure Regains Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Exicure Announces 1-for-5 Reverse Stock Split to Regain Compliance with Nasdaq’s Listing Rules

High number of new and inexperienced directors

Exicure, Inc. Appoints Anna Chukaeva as Senior Vice President, Head of Corporate Development and Bioinformatics

Exicure Receives Positive Listing Determination from Nasdaq

Exicure Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(b)(1)

Exicure, Inc., Annual General Meeting, Jun 28, 2024

Exicure, Inc. Receives Nasdaq Notice of A Delisting Determination

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. announced delayed annual 10-K filing

New minor risk - Financial data availability

No independent directors

Exicure Receives Non-Compliance Notice From Nasdaq

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. Appoints Minhee Eom to the Board

Exicure Receives Non-Compliance Notice From Nasdaq

Exicure, Inc. Announces Executive Changes

Less than half of directors are independent

Exicure Notifies Nasdaq Regarding Continued to be Not in Compliance with Rule 5605(c)(2)(A)

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

CBI USA Inc Sends a Letter to Exicure Inc

Exicure, Inc. announced delayed 10-Q filing

No independent directors

Exicure, Inc. Announces Resignation of Jeffrey L. Cleland from the Board of Directors, Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

Exicure Receives Notice from Nasdaq Regarding No Longer in Compliance with Nasdaq's Independent Director and Audit Committee Requirements

Exicure, Inc. Announces Resignation of Jiyoung Hwang from the Board of Directors

Exicure, Inc. Announces Executive Changes

Exicure, Inc. Contemplates Bankruptcy

Exicure, Inc. announced that it expects to receive $5.44 million in funding from CBI Inc.

Exicure Receives Noncompliance Notice from Nasdaq

Second quarter 2022 earnings released

Exicure Regains Compliance with Nasdaq Minimum Bid Price Requirement

Exicure Announces Receipt of Nasdaq Notice of Non-Compliance

First quarter 2022 earnings released: US$0.069 loss per share (vs US$0.14 loss in 1Q 2021)

Exicure, Inc. announced that it expects to receive $5.040289 million in funding from CBI USA, Inc, Abingworth LLP

High number of new and inexperienced directors

Exicure, Inc., Annual General Meeting, May 27, 2022

Exicure, Inc. Announces Executive, Board and Committee Changes

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Exicure, Inc. Investors

Exicure Receives A Letter from the Staff Nasdaq Stock Market

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Exicure, Inc

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.049 loss in 2Q 2020)

Exicure, Inc.(NasdaqCM:XCUR) dropped from Russell Microcap Value Index

Exicure, Inc. Advances Clinical and Pre-Clinical Pipeline Designed to Bring Therapies to Patients with Unmet Medical Needs

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2020)

Co-Founder & Director Chad Mirkin has left the company

Exicure, Inc. Announces Spherical Nucleic Acid Technology Shows Promising Results in Phase 0 Trial in Patients with Glioblastoma

Full year 2020 earnings released: US$0.28 loss per share (vs US$0.46 loss in FY 2019)

Revenue misses expectations

Exicure, Inc. Announces David R. Walt Did Not Stand for Re Election

Exicure Announces Appointments of Board of Directors

New 90-day high: €2.06

Exicure Appoints James Sulat to Board of Directors

Exicure, Inc. Announces That the U.S. Food and Drug Administration (Fda) Has Granted Fast Track Designations for Its Clinical Product Candidate

New 90-day high: €1.66

Exicure, Inc. Announces Executive Changes

New 90-day low: €1.22

Third quarter 2020 earnings released: US$0.10 loss per share

Revenue beats expectations

Exicure, Inc. Announces Resignation of Helen S. Kim as A Class II Director

Exicure Presents Updates Phase 1b Data from the Ongoing Phase 1B/2 Clinical Trial Evaluating Intratumoral Cavrotolimod

New 90-day low: €1.24

New 90-day low: €1.39

Exicure, Inc. Announces Executive Changes, Effective September 30, 2020

New 90-day low - €1.55

New 90-day low - €1.70

マネジメント基準チェック /04